Skip to main content
SpringerLink
Log in

A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli

  • Brief Report
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The use of daptomycin (DAP) in septic pulmonary emboli (SPE) remains controversial. We analyzed 29 cases of MRSA bacteremia complicated by SPE treated with DAP (n = 14) or DAP-ceftaroline fosamil (CPT; n = 15). Initial treatment with DAP monotherapy was found to have a success rate comparable with DAP-CPT (71% vs. 80%; p = 0.68).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

The data and material are available upon request.

References

  1. Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2019. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed November 14, 2019.

  2. van Hal SJ, Fowler VG Jr (2013) Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis 56:1779–1788

    Article  Google Scholar 

  3. Goswami U, Brenes JA, Punjabi GV, LeClaire MM, Williams DN (2014) Associations and outcomes of septic pulmonary emboli. Open Respir Med J 8:28–33

    Article  Google Scholar 

  4. Silverman JA, Mortin LE, VanPraagh ADG, Li T, Alder J (2005) Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191:2149–2152

    Article  CAS  Google Scholar 

  5. Crass RL, Powell KL, Huang AM (2019) Daptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli. Diagn Microbiol Infect Dis 93:131–135

    Article  CAS  Google Scholar 

  6. Wong D, Chandraratna AN, Wishnow RM, Dusitnanond V, Nimalasuriya A (1983) Clinical implications of large vegetations in infectious endocarditis. Arch Intern Med 143:1874–1877

    Article  CAS  Google Scholar 

  7. Rehm SJ, Boucher H, Levine D et al (2008) Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 62:1413–1421

    Article  CAS  Google Scholar 

  8. Kanafani Z, Boucher H, Fowler V et al (2010) Daptomycin compared to standard therapy for the treatment of native valve endocarditis. Enferm Infecc Microbiol Clin 28:498–503

    Article  Google Scholar 

  9. Werth BJ, Sakoulas G, Rose WE, Pgliano J, Tewhey R, Rybak MJ (2013) Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamics model. Antimicrob Agents Chemother 57:66–73

    Article  CAS  Google Scholar 

  10. Geriak M, Haddad F, Rizvi K et al (2019) Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 63. https://doi.org/10.1128/AAC.02483-18

  11. Fowler VG Jr, Boucher HW, Corey GR et al (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653–665

    Article  CAS  Google Scholar 

  12. Harada Y, Yanagihara K, Yamada K et al (2013) In vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of hematogenous pulmonary infection. Antimicrob Agents Chemother 57:2841–2844

    Article  CAS  Google Scholar 

  13. Kephart PA, Esposito AL (1988) Comparison of the investigational drug, LY146032, with vancomycin in experimental pneumonia due to methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 21:33–39

    Article  CAS  Google Scholar 

  14. Verghese A, Haire C, Franzus B, Smith K (1988) LY146032 in a hamster model of Staphylococcus aureus pneumonia—effect on in vivo clearance and mortality and in vitro opsonophagocytic killing. Chemotherapy 34:497–503

    Article  CAS  Google Scholar 

  15. Heine HS, Basset J, Miller L, Purcell BK, Byrne WR (2010) Efficacy of daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation. Antimicrob Agents Chemother 54:4471–4473

    Article  CAS  Google Scholar 

  16. Pertel PE, Bernardo P, Fogarty C et al (2008) Effects of prior effective therapy on the efficacy on daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 46:1142–1151

    Article  CAS  Google Scholar 

  17. Hagiya H, Hagioka S, Otsuka F (2013) Ineffectiveness of daptomycin in the treatment of septic pulmonary emboli and persistent bacteremia caused by methicillin-resistant Staphylococcus aureus. Intern Med 52:2577–2582

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA

    Taylor Morrisette, Abdalhamid M. Lagnf, Sara Alosaimy & Michael J. Rybak

  2. Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI, USA

    Michael J. Rybak

  3. Department of Pharmacy, Detroit Medical Center, Detroit, MI, USA

    Michael J. Rybak

Authors
  1. Taylor Morrisette
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdalhamid M. Lagnf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sara Alosaimy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael J. Rybak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael J. Rybak.

Ethics declarations

Conflict of interest

MJR has received grant support, consulted, or spoken on behalf of Accelerate, Allergan, Bayer, Melinta, Merck, Motif, Nabriva, Paratek, Qupex, Shionogi, and Tetraphase, and he is partially supported by NIH R01 Al12400. TM, AML, and SA have no conflicts of interest to disclose.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrisette, T., Lagnf, A.M., Alosaimy, S. et al. A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli. Eur J Clin Microbiol Infect Dis 39, 2199–2203 (2020). https://doi.org/10.1007/s10096-020-03941-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-020-03941-5

Keywords

Search

Navigation